Lampalizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lampalizumab
Monoclonal antibody
Type Fab fragment
Source Humanized (from mouse)
Target CFD
Clinical data
Routes of
administration
Intravitreal
ATC code
  • none
Legal status
Legal status
  • Phase 3 clinical trials
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C2068H3214N546O676S13
Molar mass 46.96 kg/mol

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration. It binds to complement factor D (CFD).[1][2]

Enrollment in Phase 3 clinical trials was initiated in 2014.[3] Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.[4]

References[edit]

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
  3. ^ Roche starts Phase III trials of lampalizumab, PharmaTimes
  4. ^ What are clinical trial phases?, NIH - US National Library of Medicine.